RxDoctor Payments DataLook up a doctor →

Erum Shahab, MD

Psychiatry · Ellington, CTNPI 1669434049

Payments from drug & device makers

$15,811in general payments, 2019–2025

Across 846 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Bausch Health US, LLC$2K
  • Sunovion Pharmaceuticals Inc.$2K
  • Vanda Pharmaceuticals Inc.$2K
  • Johnson & Johnson$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • plus $6K from 20 others

What the payments were for

  • Food & beverage$15,72999%
  • Education$821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,811 in reported general payments places this provider in the 90th percentile of 644 psychiatry providers in Connecticut.

See all psychiatry providers in Connecticut

Medicare billing

Part B allowed, 2024
$10,335
Medicare patients
26
Services billed
111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl26$32,093
Lurasidone Hcl29$7,521
Clozapine68$5,010
Aripiprazole102$3,780
Duloxetine Hcl131$2,797
Perphenazine16$2,579
Hydroxyzine Hcl73$2,232
Glycopyrrolate12$1,656
Bupropion XlBupropion Hcl64$1,534
Atomoxetine Hcl11$1,473
Fluoxetine Hcl126$1,194
Trazodone Hcl133$1,088
Divalproex Sodium32$1,071
Lamotrigine73$946
Sertraline Hcl61$797

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$1,419$32,09326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 644 psychiatry providers in Connecticut.

Other psychiatry in Ellington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →